Computational Fluid Dynamics Predicting Intraprosthetic Thrombus Formation and Progression Following EVAR
Computational Fluid Dynamics Predicting Intraprosthetic Thrombus Formation and Progression Following Endovascular Aortic Repair: a Two-center Retrospective Study
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Actual)
Enrollment
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Aged 18 and above;
- Patients undergone endovascular aneurysm repair;
- Signed informed consent forms, willing to receive treatments.
Exclusion Criteria:
- inflammatory aortic aneurysm;
- patients diagnosed with connective tissue diseases;
- patients diagnosed with atrial fibrillation;
- patients lacking post-operative CTA;
- Patients who are participating in other clinical projects;
- Patients are not suitable to participate in this study.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Intraprosthetic thrombus Group
presence of intraprosthetic thrombus according to the postoperative CTA
|
|
Non-intraprosthetic thrombus Group
absence of intraprosthetic thrombus according to the postoperative CTA
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Degree of intraprosthetic thrombus in limb graft
Time Frame: From January 2014 to June 2024
|
Evaluate the area of thrombus occupying the lumen using postoperative CTA
|
From January 2014 to June 2024
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Disease-related complications
Time Frame: From January 2014 to June 2024
|
Disease-related complications associated with intraprosthetic thrombus or limb graft occlusion, such as thromboembolic events
|
From January 2014 to June 2024
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2024030373
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.